1. Home
  2. NTCT vs AUPH Comparison

NTCT vs AUPH Comparison

Compare NTCT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetScout Systems Inc.

NTCT

NetScout Systems Inc.

HOLD

Current Price

$27.77

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.72

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTCT
AUPH
Founded
1984
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
1999
1999

Fundamental Metrics

Financial Performance
Metric
NTCT
AUPH
Price
$27.77
$15.72
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$32.00
$17.25
AVG Volume (30 Days)
492.9K
1.6M
Earning Date
01-29-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.24
0.55
Revenue
$862,770,000.00
$265,808,000.00
Revenue This Year
$5.90
$21.22
Revenue Next Year
$2.62
$15.40
P/E Ratio
$22.19
$28.81
Revenue Growth
9.60
20.62
52 Week Low
$18.12
$6.55
52 Week High
$30.67
$16.48

Technical Indicators

Market Signals
Indicator
NTCT
AUPH
Relative Strength Index (RSI) 56.70 57.76
Support Level $27.44 $15.15
Resistance Level $28.20 $16.03
Average True Range (ATR) 0.53 0.50
MACD 0.10 -0.12
Stochastic Oscillator 76.37 57.02

Price Performance

Historical Comparison
NTCT
AUPH

About NTCT NetScout Systems Inc.

NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: